Caring Brands (CABR) investor relations material

Company overview and business model

• Operates as a wellness consumer products company offering OTC and cosmetic products for skin and hair conditions, including Photocil (for vitiligo and psoriasis), Hair Enzyme Booster (JW-700), CB-101 (eczema), and No Stingz (sunscreen/jellyfish protection).

• Business model emphasizes clinically validated, patent-protected products with established mechanisms of action and commercial stability.

• Products are sold through e-commerce platforms, licensing agreements, and international distribution, with a focus on direct-to-consumer and B2B channels.

• Recent expansion includes a license for an Ebola Rapid Test and ongoing development of new wellness products.

Financial performance and metrics

• Nominal revenues reported: $3,056 for the six months ended June 30, 2025, and $465 for the period April 24 to December 31, 2024.

• Net losses: $1,199,353 for the six months ended June 30, 2025, and $862,791 for the period April 24 to December 31, 2024.

• Cash and cash equivalents were $73,893 as of June 30, 2025.

• Operating expenses driven by stock-based compensation, professional fees, and salaries; company has a working capital deficit and is dependent on external financing.

• Auditor issued a going concern warning due to recurring losses and negative cash flows.

Use of proceeds and capital allocation

• Net proceeds of ~$3.2 million from the IPO will fund product development, manufacturing, marketing, clinical testing, repayment of related party loans, legal/compliance, and general working capital.

• Major allocations: $700,000 for Hair Enzyme Booster, $505,000 for Photocil, $385,000 for CB-101, $310,000 for No Stingz, and $250,000 for general working capital.

• Proceeds are expected to fund operations for approximately 12 months.